"www.healthbusiness.nl"

FRIDAY, Jan. 27 — Bydureon (exenatide extended release), Amylin Pharmaceuticals’ long-acting version of the diabetes drug Byetta, has been approved by the U.S. Food and Drug Administration.
The once-weekly injection will include a label warning…

Lees meer..

This entry was posted on Saturday, January 28th, 2012 at 6:00 am and is filed under Medicijnen. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.